[Skip to Content]
Upstate Hospital Logo
MENU

Upstate Active Clinical Trials

Study Title:

S1925 - A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study

What is the purpose of the study? (in Layman's terms, please describe the study)

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with the venetoclax and obinutuzumab early (before patients have symptoms) may have better outcomes for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma compared to starting treatment with the venetoclax and obinutuzumab after patients show symptoms.

Upstate Institutional Review Board (IRB) Number:

1978509

Study/Protocol ID:

S1925

Study Phase:

III

Patient Age Group:

Adults

Principal Investigator:

Krishna B Ghimire, MD

What is involved if I participate?

  • How long is the study?
    UNK
  • Is transportation provided or reimbursed?
    No
  • Is parking provided or reimbursed?
    No
  • What tests and procedures are involved?
    Questionnaires, Blood draws, Bone marrow biopsy, CT Scans

Where will the study take place?

SUNY Upstate Medical University
Upstate Cancer Center Hematology Oncology at Community
Upstate Cancer Center Hematology Oncology at Oneida
Upstate Cancer Center Hematology Oncology at Oswego

Other Information:

N/A

ClinicalTrials.Gov ID:

NCT04269902

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Kelsey F Christo, MS BS
Phone: 315-464-5751
Email: [email protected]

Return to Previous Page || Search Again

Top